Published in Nat Rev Immunol on January 18, 2010
The interleukin-1 family: back to the future. Immunity (2013) 3.90
IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A (2010) 3.07
The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol (2010) 2.74
Innate and adaptive immune responses in asthma. Nat Med (2012) 2.73
The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol (2011) 2.33
Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest (2014) 2.31
Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A (2010) 2.22
Apoptotic cell clearance by bronchial epithelial cells critically influences airway inflammation. Nature (2012) 2.18
Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J Allergy Clin Immunol (2011) 2.12
IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A (2012) 1.99
Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut (2012) 1.97
Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. J Allergy Clin Immunol (2013) 1.73
IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol (2011) 1.72
Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity (2013) 1.67
Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nat Med (2015) 1.63
Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. Nat Genet (2012) 1.58
Regulation of mast cell responses in health and disease. Crit Rev Immunol (2011) 1.50
Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest (2013) 1.42
IL-33 family members and asthma - bridging innate and adaptive immune responses. Curr Opin Immunol (2010) 1.41
Danger signals activating the immune response after trauma. Mediators Inflamm (2012) 1.40
Regulation of innate CD8+ T-cell activation mediated by cytokines. Proc Natl Acad Sci U S A (2012) 1.38
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther (2016) 1.37
Constitutive interferon-inducible protein 16-inflammasome activation during Epstein-Barr virus latency I, II, and III in B and epithelial cells. J Virol (2013) 1.33
Multi-walled carbon nanotube instillation impairs pulmonary function in C57BL/6 mice. Part Fibre Toxicol (2011) 1.33
IL-33 synergizes with TCR and IL-12 signaling to promote the effector function of CD8+ T cells. Eur J Immunol (2011) 1.32
Identification of an IFN-γ/mast cell axis in a mouse model of chronic asthma. J Clin Invest (2011) 1.27
Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front Neurosci (2014) 1.26
Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res (2014) 1.23
Lineage(-)Sca1+c-Kit(-)CD25+ cells are IL-33-responsive type 2 innate cells in the mouse bone marrow. J Immunol (2011) 1.22
Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J Immunol (2012) 1.22
Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol (2010) 1.21
Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int (2014) 1.18
The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood (2015) 1.18
Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol (2012) 1.15
Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci (2011) 1.11
IL-33 markedly activates murine eosinophils by an NF-κB-dependent mechanism differentially dependent upon an IL-4-driven autoinflammatory loop. J Immunol (2013) 1.10
ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol (2011) 1.10
Macrophages as IL-25/IL-33-responsive cells play an important role in the induction of type 2 immunity. PLoS One (2013) 1.09
IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2+ regulatory T cells. J Immunol (2014) 1.09
Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma. Am J Respir Crit Care Med (2014) 1.09
Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci U S A (2013) 1.09
Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol (2013) 1.08
IL-33-dependent induction of allergic lung inflammation by FcγRIII signaling. J Clin Invest (2013) 1.08
Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis (2012) 1.07
Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation. Therap Adv Gastroenterol (2011) 1.07
IL-1 family cytokines trigger sterile inflammatory disease. Front Immunol (2012) 1.07
Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology (2013) 1.07
DNA methylation and childhood asthma in the inner city. J Allergy Clin Immunol (2015) 1.07
Early detection of myocardial dysfunction and heart failure. Nat Rev Cardiol (2010) 1.06
Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy (2012) 1.06
IL-33 exacerbates acute kidney injury. J Am Soc Nephrol (2011) 1.05
IL-33: a novel danger signal system in atopic dermatitis. J Invest Dermatol (2012) 1.05
Interleukin 33 is a guardian of barriers and a local alarmin. Nat Immunol (2016) 1.04
Amplification of cytokine production through synergistic activation of NFAT and AP-1 following stimulation of mast cells with antigen and IL-33. Eur J Immunol (2011) 1.03
Blockade of IL-33 release and suppression of type 2 innate lymphoid cell responses by helminth secreted products in airway allergy. Mucosal Immunol (2014) 1.03
IL-33 induces IL-9 production in human CD4+ T cells and basophils. PLoS One (2011) 1.02
Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells. Proc Natl Acad Sci U S A (2014) 1.02
Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis B. J Interferon Cytokine Res (2012) 1.01
Interleukin 33: a switch-hitting cytokine. Curr Opin Immunol (2014) 1.01
Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients. Clin Immunol (2011) 1.01
Chronic proliferative dermatitis in Sharpin null mice: development of an autoinflammatory disease in the absence of B and T lymphocytes and IL4/IL13 signaling. PLoS One (2014) 1.00
Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol (2014) 1.00
IL-33-mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells. PLoS Pathog (2015) 0.99
Comparative study of the cytokine/chemokine response in children with differing disease severity in enterovirus 71-induced hand, foot, and mouth disease. PLoS One (2013) 0.99
Proinflammatory and regulatory cytokines and chemokines in infants with uncomplicated and severe Plasmodium falciparum malaria. Clin Exp Immunol (2011) 0.98
Interleukin-33 potentiates bleomycin-induced lung injury. Am J Respir Cell Mol Biol (2013) 0.98
Innate immunological function of TH2 cells in vivo. Nat Immunol (2015) 0.98
MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease. Nat Commun (2015) 0.98
Disordered IL-33/ST2 activation in decidualizing stromal cells prolongs uterine receptivity in women with recurrent pregnancy loss. PLoS One (2012) 0.98
Different Members of the IL-1 Family Come Out in Different Ways: DAMPs vs. Cytokines? Front Immunol (2013) 0.98
Immunopathological roles of cytokines, chemokines, signaling molecules, and pattern-recognition receptors in systemic lupus erythematosus. Clin Dev Immunol (2012) 0.98
Cardiovascular biomarkers in acute Kawasaki disease. Int J Cardiol (2011) 0.98
Intravenously delivered graphene nanosheets and multiwalled carbon nanotubes induce site-specific Th2 inflammatory responses via the IL-33/ST2 axis. Int J Nanomedicine (2013) 0.97
Decoys and Regulatory "Receptors" of the IL-1/Toll-Like Receptor Superfamily. Front Immunol (2013) 0.96
The IL-33-ST2L pathway is associated with coronary artery disease in a Chinese Han population. Am J Hum Genet (2013) 0.96
Genetics of interleukin 1 receptor-like 1 in immune and inflammatory diseases. Curr Genomics (2010) 0.95
Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis C. Mediators Inflamm (2012) 0.95
Paracrine IL-33 stimulation enhances lipopolysaccharide-mediated macrophage activation. PLoS One (2011) 0.93
Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis. PLoS One (2012) 0.92
Emerging role of interleukin-33 in autoimmune diseases. Immunology (2014) 0.92
Mast cells. Curr Gastroenterol Rep (2010) 0.92
IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. Proc Natl Acad Sci U S A (2016) 0.92
The role of IL-33 and mast cells in allergy and inflammation. Clin Transl Allergy (2015) 0.91
Mast Cells Respond to Cell Injury through the Recognition of IL-33. Front Immunol (2012) 0.91
Mechanisms of tolerance and allergic sensitization in the airways and the lungs. Curr Opin Immunol (2010) 0.90
Classical versus alternative macrophage activation: the Ying and the Yang in host defense against pulmonary fungal infections. Mucosal Immunol (2014) 0.90
Respiratory Syncytial Virus Disease Is Mediated by Age-Variable IL-33. PLoS Pathog (2015) 0.89
Implications for Interleukin-33 in solid organ transplantation. Cytokine (2013) 0.89
Deletion of IL-33R (ST2) abrogates resistance to EAE in BALB/C mice by enhancing polarization of APC to inflammatory phenotype. PLoS One (2012) 0.89
IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J Clin Invest (2015) 0.89
Novel identified receptors on mast cells. Front Immunol (2012) 0.88
IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects. BMC Immunol (2014) 0.88
IL-33 independently induces eosinophilic pericarditis and cardiac dilation: ST2 improves cardiac function. Circ Heart Fail (2012) 0.88
IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. Mucosal Immunol (2014) 0.87
IL-33 attenuates the development of experimental autoimmune uveitis. Eur J Immunol (2014) 0.87
IL-33-induced alterations in murine intestinal function and cytokine responses are MyD88, STAT6, and IL-13 dependent. Am J Physiol Gastrointest Liver Physiol (2012) 0.87
Eosinophil adoptive transfer system to directly evaluate pulmonary eosinophil trafficking in vivo. Proc Natl Acad Sci U S A (2013) 0.87
Human Th2 but not Th9 cells release IL-31 in a STAT6/NF-κB-dependent way. J Immunol (2014) 0.87
Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood (2016) 0.87
Interleukin-33 increases antibacterial defense by activation of inducible nitric oxide synthase in skin. PLoS Pathog (2014) 0.86
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 19.77
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005) 14.95
DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol (2006) 10.73
IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A (2006) 5.08
IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev (2008) 4.68
The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One (2008) 4.52
Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity (2009) 4.49
Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity (2008) 4.37
IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest (2007) 4.31
HMGB1: endogenous danger signaling. Mol Med (2008) 4.02
T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A (1998) 3.61
IL-33 reduces the development of atherosclerosis. J Exp Med (2008) 3.59
Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell (2008) 3.58
Alarmins: chemotactic activators of immune responses. Curr Opin Immunol (2005) 3.57
Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med (1998) 3.53
IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol (2009) 3.41
The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A (2009) 3.39
IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol (2008) 3.31
Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol (2008) 3.27
Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem (2007) 3.11
IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol (2008) 3.09
IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A (2008) 2.99
Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol (2007) 2.99
IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol (2007) 2.93
Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med (1999) 2.92
IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol (2008) 2.83
A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol (2008) 2.78
Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol (2003) 2.72
Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation (2002) 2.65
Targeted peptidecentric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. Mol Cell Proteomics (2008) 2.64
Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation (2003) 2.62
Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation (2004) 2.52
IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol (2007) 2.43
Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol (2009) 2.42
IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol (2007) 2.38
IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest (2007) 2.37
Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine (2007) 2.33
The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med (1999) 2.32
IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A (2007) 2.27
Retracted The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A (2009) 2.15
Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying cells. J Immunol (2008) 2.13
A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett (1989) 2.07
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum (2009) 2.03
Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem (2009) 2.00
An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol (2008) 1.96
The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol (2009) 1.95
IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol (2009) 1.92
Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med (2009) 1.72
Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun (2009) 1.71
Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep (2008) 1.68
IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc Natl Acad Sci U S A (2008) 1.67
Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest (2008) 1.64
Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol (2008) 1.59
A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol (2004) 1.55
IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol (2009) 1.54
Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J Exp Med (2001) 1.51
Identification of a nuclear localization sequence within the structure of the human interleukin-1 alpha precursor. J Biol Chem (1993) 1.51
Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry (2009) 1.51
T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation. Eur J Immunol (2007) 1.50
Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1. FEBS Lett (1993) 1.50
Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab (1999) 1.35
Mast cells modulate allergic pulmonary eosinophilia in mice. Am J Respir Cell Mol Biol (1995) 1.32
Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem Biophys Res Commun (2009) 1.26
Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun (2001) 1.20
Induction of a mitogen-responsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Mol Cell Biol (1989) 1.15
TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell Signal (2008) 1.13
Elevation of ST2 protein levels in cerebrospinal fluid following subarachnoid hemorrhage. Acta Neurol Scand (2006) 0.90
The effect of ST2 gene product on anchorage-independent growth of a glioblastoma cell line, T98G. Eur J Biochem (2003) 0.87
Role of cell type-specific promoters in the developmental regulation of T1, an interleukin 1 receptor homologue. Cell Growth Differ (1995) 0.83
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 6.24
Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation (2003) 4.52
Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest (2008) 3.90
IL-33 reduces the development of atherosclerosis. J Exp Med (2008) 3.59
IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol (2009) 3.41
MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci U S A (2011) 3.37
IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A (2008) 2.99
IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol (2007) 2.82
Interleukin-18. J Leukoc Biol (2003) 2.75
Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol (2010) 2.64
IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol (2007) 2.43
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum (2005) 2.37
A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol (2003) 2.37
Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail (2013) 2.17
Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol (2010) 1.92
A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol (2004) 1.88
Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum (2013) 1.84
Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res (2010) 1.80
Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production. J Immunol (2012) 1.71
Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nat Rev Cardiol (2009) 1.68
A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells. Ann Rheum Dis (2011) 1.63
IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann Rheum Dis (2010) 1.62
Animal models of rheumatoid arthritis. Eur J Immunol (2009) 1.57
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med (2015) 1.56
A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol (2004) 1.55
25-Hydroxyvitamin D is lower in deprived groups, but is not associated with carotid intima media thickness or plaques: results from pSoBid. Atherosclerosis (2012) 1.46
The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med (2015) 1.42
IL-33 exacerbates autoantibody-induced arthritis. J Immunol (2010) 1.40
Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum (2012) 1.40
CXCR2-specific chemokines mediate leukotriene B4-dependent recruitment of neutrophils to inflamed joints in mice with antigen-induced arthritis. Arthritis Rheum (2008) 1.39
Prostaglandin mediates IL-23/IL-17-induced neutrophil migration in inflammation by inhibiting IL-12 and IFNgamma production. Proc Natl Acad Sci U S A (2009) 1.31
Optimization of current and future therapy for autoimmune diseases. Nat Med (2012) 1.29
Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann Rheum Dis (2010) 1.28
Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther (2006) 1.27
How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy. Nat Med (2013) 1.26
IL-18 enhances collagen-induced arthritis by recruiting neutrophils via TNF-alpha and leukotriene B4. J Immunol (2003) 1.26
A novel dendritic cell-induced model of erosive inflammatory arthritis: distinct roles for dendritic cells in T cell activation and induction of local inflammation. J Immunol (2002) 1.22
Ultrasound guided versus conventional joint and soft tissue fluid aspiration in rheumatology practice: a pilot study. J Rheumatol (2002) 1.21
Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol (2013) 1.20
Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis (2012) 1.19
Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum (2007) 1.19
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis (2012) 1.17
Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol (2013) 1.17
Distinct roles of sphingosine kinase 1 and 2 in murine collagen-induced arthritis. J Immunol (2009) 1.16
Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis. J Immunol (2008) 1.16
Inflammation is present in early human tendinopathy. Am J Sports Med (2010) 1.12
IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J Immunol (2011) 1.12
IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol (2011) 1.11
Plasmacytoid dendritic cells play a key role in promoting atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2012) 1.11
Looking through the 'window of opportunity': is there a new paradigm of podiatry care on the horizon in early rheumatoid arthritis? J Foot Ankle Res (2010) 1.11
Hypoxia: a critical regulator of early human tendinopathy. Ann Rheum Dis (2011) 1.10
Immune regulation in psoriasis and psoriatic arthritis--recent developments. Immunol Lett (2007) 1.10
Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjögren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate. Arthritis Res Ther (2004) 1.10
Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol (2005) 1.10
Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium: ex vivo studies using a novel proteinase-activated receptor 2 antagonist. Arthritis Rheum (2007) 1.08
Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP- dendritic cells with distinct cytokine profiles. Am J Pathol (2008) 1.07
Plasmacytoid dendritic cells regulate breach of self-tolerance in autoimmune arthritis. J Immunol (2009) 1.07
IL-15 mediates antigen-induced neutrophil migration by triggering IL-18 production. Eur J Immunol (2007) 1.06
A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. Ann Rheum Dis (2012) 1.05
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. Ann Rheum Dis (2012) 1.05
Universal expression and dual function of the atypical chemokine receptor D6 on innate-like B cells in mice. Blood (2011) 1.04
MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS One (2013) 1.04
Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. J Rheumatol (2007) 1.02
Images in cardiovascular medicine. Multiphoton microscopy for 3-dimensional imaging of lymphocyte recruitment into apolipoprotein-E-deficient mouse carotid artery. Circulation (2007) 1.02
TNF-blocking therapies: an alternative mode of action? Trends Immunol (2005) 1.02
Influence of periodontal disease, Porphyromonas gingivalis and cigarette smoking on systemic anti-citrullinated peptide antibody titres. J Clin Periodontol (2013) 1.02
Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis. Arthritis Rheum (2013) 1.01
Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol (2015) 1.00
Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1. J Immunol (2008) 0.99
Abatacept limits breach of self-tolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol (2010) 0.99
Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheumatol (2007) 0.98
Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann Rheum Dis (2011) 0.98
Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1. J Immunol (2008) 0.97
Liver X receptor agonism promotes articular inflammation in murine collagen-induced arthritis. Arthritis Rheum (2009) 0.96
Novel regulatory mechanisms in inflammatory arthritis: a role for microRNA. Immunol Cell Biol (2012) 0.96
A TLR2 ligand suppresses inflammation by modulation of chemokine receptors and redirection of leukocyte migration. Blood (2009) 0.95
An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Ann Rheum Dis (2011) 0.95
Chemoattraction of human T cells by IL-18. J Immunol (2003) 0.95
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology (Oxford) (2013) 0.95
The role of innate mediators in inflammatory response. Mol Immunol (2002) 0.95
Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS One (2012) 0.94
ES-62, a filarial nematode-derived immunomodulator with anti-inflammatory potential. Immunol Lett (2004) 0.94
Murine neutrophils present Class II restricted antigen. Immunol Lett (2008) 0.94
New cytokine targets in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol (2006) 0.94
Inducing experimental arthritis and breaking self-tolerance to joint-specific antigens with trackable, ovalbumin-specific T cells. J Immunol (2004) 0.92
Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions. Expert Opin Biol Ther (2007) 0.92
Enhanced Th1 response to Staphylococcus aureus infection in human lactoferrin-transgenic mice. J Immunol (2002) 0.91
A reliability study of biomechanical foot function in psoriatic arthritis based on a novel multi-segmented foot model. Gait Posture (2010) 0.90
Expression and alternative processing of IL-18 in human neutrophils. Eur J Immunol (2006) 0.90
Elevated expression of the chemokine-scavenging receptor D6 is associated with impaired lesion development in psoriasis. Am J Pathol (2012) 0.90
Markedly increased IL-18 liver expression in adult-onset Still's disease-related hepatitis. Rheumatology (Oxford) (2010) 0.90
Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk. Arterioscler Thromb Vasc Biol (2011) 0.90
Identifying the cells breaching self-tolerance in autoimmunity. J Immunol (2010) 0.89
Protease-activated receptor 2: a novel pathogenic pathway in a murine model of osteoarthritis. Ann Rheum Dis (2010) 0.89
What can the periodontal community learn from the pathophysiology of rheumatoid arthritis? J Clin Periodontol (2011) 0.89
Correlation of protease-activated receptor-2 expression and synovitis in rheumatoid and osteoarthritis. Rheumatol Int (2011) 0.88